New-Onset and Exacerbation of Psoriasis following COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series DOI Creative Commons

Aisyah N. F. Arifin,

Antoninus Hengky,

Maureen Widjaja

et al.

Indian Journal of Dermatology, Journal Year: 2023, Volume and Issue: 68(6), P. 724 - 724

Published: Nov. 1, 2023

Abstract Introduction: Although uncommon, several cases of new-onset and exacerbation psoriasis have been reported after coronavirus disease 2019 (COVID-19) vaccination. This study aims to systematically review reports regarding identify features related that condition following COVID-19 Materials Methods: Three databases were utilised, namely, PubMed, Google Scholar, EBSCOHost search for literature published until June 2022. We used the MeSH terms: “psoriasis,” “exacerbation,” “induced psoriasis,” “COVID-19 vaccination.” The included must report case/(s) in previously-in-remission or induced individuals receiving any dose vaccines regardless type. Results: Among 33 selected studies, an overall mean age was 57.52 ± 15.92 years. Female ( n = 40; 54.8%) more frequently than male 33; 45.2%). In terms vaccine types, Pfizer is most commonly (49 cases; 67.1%), followed by Astra-Zeneca (13 17.8%), Moderna (10 13.7%), CoronaVac (1 case; 1.4%). onset Vaccines varied, ranging from 1 90 days (Mean SD: 15.75 18.22). Plaque reported, pustular, guttate other types psoriasis. Reported treated with topical steroids monoclonal antibodies monotherapy. Conclusions: vaccination quite scarce, possibility occurrence should be acknowledged managed properly; patients informed, particularly ones history without discouraging take vaccine.

Language: Английский

New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review DOI Open Access
Po‐Chien Wu, I‐Hsin Huang, Chuang‐Wei Wang

et al.

American Journal of Clinical Dermatology, Journal Year: 2022, Volume and Issue: 23(6), P. 775 - 799

Published: Sept. 1, 2022

Language: Английский

Citations

50
Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study DOI Open Access
Gianluca Avallone, Carlo Alberto Maronese,

Giulia Murgia

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(4), P. 1662 - 1662

Published: Feb. 19, 2023

Pustular and erythrodermic psoriasis are rare difficult-to-treat conditions. It has recently been shown that interleukin (IL)-17 inhibitors can be very effective among patients with these forms of psoriasis; however, the potential IL-23 is largely unknown. The aim this multicentre, retrospective study was to compare safety, effectiveness, drug survival IL-17 affected by psoriasis. involved 27 59 pustular (36 generalised 23 palmoplantar psoriasis) treated an or inhibitor. effectiveness two classes assessed using disease-specific Psoriasis Area Severity Index (PASI) Investigator Global Assessment, which were evaluated at different time points. There a consistent trend towards higher rate PASI 100 responses in compared those inhibitors, other efficacy outcomes showed similar trend. no significant between-drug class difference any points cohort, whereas 90 response rates significantly receiving week 12 (IL-23 19% vs. 54% 6% 40%, respectively) percentage responders inhibition 24 25% 74%). In conclusion, it therefore reasonable assume both when treating

Language: Английский

Citations

25
Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters DOI Creative Commons
Emmanouil Karampinis, Myrto-Maria Papadopoulou,

Kleoniki Chaidaki

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(2), P. 178 - 178

Published: Feb. 9, 2024

The diverse patient population and widespread vaccination in the COVD-19 era make vaccine-triggered episodes of psoriasis an ideal model exposome research. This scenario explores fine balance between protective exacerbating factors, providing insights into complex relationship environmental exposure immunopathogenesis when a trigger appears, such as that hyperinflammatory state induced by COVID-19 vaccine. Analyzing interactions vaccine-induced phenomena parameters may provide clinically relevant information important for personalized medicine decision-making. We performed literature review seeking patients with plaque flares or new onset change another subtype, pustular erythrodermic flare, focusing on inner external traits patients. identified 71 flares, 12 new-onset psoriasis, 17 subtype change, assessed terms clinical presentation, post-vaccination flare period treatment status, well (genomics, oxidative stress, hormonal impact due to gender, aging, skin color) (UV, infectomics). Novel data following are primarily obtained combining episode features characteristics comparing them similar unrelated vaccination.

Language: Английский

Citations

13
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? DOI Creative Commons
Matteo Megna, Elisa Camela, Angelo Ruggiero

et al.

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2023, Volume and Issue: Volume 16, P. 1677 - 1690

Published: June 1, 2023

Abstract: Generalized pustular psoriasis (GPP) is a severe and rare form of psoriasis, being potentially life-threatening condition, characterized by recurring episodes or flares widespread cutaneous erythema with macroscopic sterile pustules. An irregular innate immune response linked to GPP, which considered an auto-inflammatory disorder, while adaptive immunopathogenic responses are involved in pathogenesis. In consequence, different cytokine cascades have been suggested be mainly the pathogenesis each form, interleukin (IL)23/IL17 axis implied plaque IL36 pathway GPP. As regards GPP treatment, conventional systemic drugs available for usually used as first-line treatment option. However, contraindications adverse events often limit use these therapies. this scenario, biologic may represent promising To date, even if 12 biologics approved none where they employed off-label. Recently, spesolimab, anti-IL36 receptor monoclonal antibody, has recently The purpose article assess current literature about biological therapies establish basis shared management algorithm. Keywords:

Language: Английский

Citations

20
Pustular Eruption following COVID-19 Vaccination: A Narrative Case-Based Review DOI Creative Commons
Emmanouil Karampinis, Agoritsa Gravani,

Polyxeni Gidarokosta

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(8), P. 1298 - 1298

Published: July 29, 2023

From the beginning of public vaccinations until relaxation COVID-19 measures, many case reports, series and case–control studies have been published indicating cutaneous side effects vaccination. Post-vaccination pustular eruption was reported as well, with a challenging differential diagnosis between psoriasis, AGEP (acute generalized exanthematous pustulosis) neutrophil eruptions. We report 56-year-old woman presented acute flare up culminated 5 days after second dose BNT162b2(Pfizer) She diagnosed psoriasis due to regulating role IL-1 in cytokine storm observed cases postvaccination inflammation; we decided treat patient an antagonist, subcutaneous anakinra (100 mg daily) along acitretin. One week later, withdrawal, she 7-day re-administration led satisfactory improvement skin lesions. also reviewed medical literature found 28 reports compared patients reported, regarding sex, age, number doses, post-vaccination period vaccine brand, those results our patient. Finally, indicated by other similarly treated targeted therapy this imbalance such (IL-1) antagonist can improve clinical course

Language: Английский

Citations

14
New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series DOI Creative Commons
Luigi Gargiulo, Luciano Ibba, Carlo Alberto Vignoli

et al.

Journal of Dermatological Treatment, Journal Year: 2023, Volume and Issue: 34(1)

Published: March 30, 2023

Since the worldwide spreading COVID-19 pandemic from early 2020 onwards, several cutaneous manifestations of SARS-CoV2 infection have been described. Similarly, with start global vaccination campaign, reports new onset or exacerbation inflammatory dermatoses reported. In particular, numerous case psoriasis flares after and/or recently published.Our study aimed to evaluate effectiveness and safety anti-interleukin (IL) biologic drugs for treatment severe following vaccination.Twenty-eight patients a diagnosis moderate-to-severe flare previously untreated mild plaque psoriasis, all treated biologics, were enrolled in this study.After 16 weeks treatment, mean Psoriasis Area Severity Index decreased 13.65 0.77, (57.14%) achieving complete skin clearance.In our study, we underline high-effectiveness profile different biological treating induced by infection. Our data support role biologics preventing despite possible concomitant triggers, such as infections vaccines.

Language: Английский

Citations

12
Management of Chronic Generalized Pustular Psoriasis: A Review and Expert Opinion DOI Creative Commons
Boni E. Elewski,

Mark Lebwohl

Journal of Psoriasis and Psoriatic Arthritis, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 2, 2025

Introduction: Generalized pustular psoriasis (GPP) is a rare, chronic inflammatory skin disease characterized by persistent symptoms and sudden flares of painful sterile pustules, sometimes accompanied systemic inflammation. Patients with GPP experience burden even when not experiencing flares. There an unmet need for guidelines on continuous long-term management this disease. Areas Covered: This review summarizes existing literature describing the GPP, persistence effects quality life (QoL) patients are flare, recurring nature flares, high prevalence comorbidities. We also present overview results from EFFISAYIL® 2 study, which was first randomized, placebo-controlled clinical trial to systematically evaluate subcutaneous spesolimab, first-in-class anti-interleukin-36 receptor monoclonal antibody specifically designed treat GPP. Expert Opinion: An in establishment management, including measures treating between flare prevention, control. Treatment strategies should mitigate both potentially life-threatening episodes. Intravenous spesolimab currently only FDA-approved medication flare. Guidelines aim advance recognition as emphasize prompt diagnosis timely access therapies according diagnostic criteria established International Psoriasis Council National Foundation.

Language: Английский

Citations

0
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature DOI Creative Commons
Fabrizio Martora, Teresa Battista, Claudio Marasca

et al.

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2022, Volume and Issue: Volume 15, P. 2369 - 2382

Published: Nov. 1, 2022

Abstract: The outbreak of coronavirus disease 2019 (COVID-19) represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain widespread infection. Among these, vaccination is currently most important measure fight against pandemic. However, concerns such as slower-than-hoped-for rollout, hurried approval with limited data, mechanism action (in particular mRNA-based), uncertain duration protection they afforded were initially raised. Moreover, even if cutaneous reactions rarely reported in clinical trials, mass showed dermatologic not recognized, leaving dermatologists decide how diagnose treat them. In this scenario, should be ready promptly recognize these manifestations. Thus, aim manuscript review current literature following COVID-19 vaccination, particularly inflammatory dermatological diseases, order help clinicians better understand conditions provide an extensive overview all vaccine-related skin Keywords: reactions, vaccinations, side effects

Language: Английский

Citations

17
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study DOI Open Access
Giovanni Fiorillo, Luciano Ibba, Luigi Gargiulo

et al.

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(2), P. 186 - 186

Published: Feb. 7, 2024

Psoriasis can have a significant impact on quality of life and productivity, especially with increased severity. However, there is limited evidence biologics’ efficacy in highly severe cases compared to moderate-to-severe ones. This study aimed evaluate the effectiveness safety novel biological therapies very psoriasis. We conducted retrospective analysis patients ≥ 18 years old affected by psoriasis who had received agent for at least 16 weeks. used PASI assess disease severity weeks 16, 52, 104, 156. Safety was evaluated tracking treatment discontinuation rates adverse events. included 29 males 11 females, mean age 55.80 (SD 13.82). Cardiometabolic diseases were most common comorbidities (25.00%). Twenty-eight (70.00%) involvement one difficult-to-treat area. All completed treatment. The 31.60 2.57) baseline, 3.48 4.13) week 0.58 1.70) 0.77 1.66) 1.29 2.12) PASI90 100 achieved 52.50% 30.00% 96.15% 80.77% 93.33% 66.67% 85.71% 42.86% PASIs ≤ 2 50.00% 88.46% 86.67% Only two discontinued biologics due complete remission, mild AEs reported four patients. Our findings show that are effective well tolerated treating psoriasis, maintaining long-term effectiveness.

Language: Английский

Citations

3
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge DOI Creative Commons
Luca Potestio, Teresa Battista, Sara Cacciapuoti

et al.

Biomedicines, Journal Year: 2023, Volume and Issue: 11(8), P. 2191 - 2191

Published: Aug. 3, 2023

COVID-19 vaccination was the main measure to overcome pandemic. As with other drugs and vaccines, mild moderate adverse events have been reported following vaccination. In addition, several cutaneous reactions described. particular, there are reports investigating de novo psoriasis or exacerbation of However, data on possible pathogenetic mechanisms as well comprehensive manuscripts topic scant. Thus, aim our manuscript perform a review current literature post-COVID-19 exacerbations new-onset in order offer wide perspective this area point out mechanisms. Research performed PRISMA guidelines. total, 49 studies involving 134 patients developing (n = 27, 20.1%) 107, 79.9%) were collected. Although cases worsening vaccination, all successfully treated while overall benefit–risk profile does not justify vaccine hesitancy due risk being developed worsening. Certainly, further needed identify “at-risk” patients. Finally, should be discouraged.

Language: Английский

Citations

7